Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 31;75(3):453-459.
doi: 10.1093/cid/ciab971.

Ledipasvir/Sofosbuvir for Patients Coinfected With Chronic Hepatitis C and Hepatitis B in Taiwan: Follow-up at 108 Weeks Posttreatment

Chun Jen Liu  1 , I Shyan Sheen  2 , Chi Yi Chen  3 , Wan Long Chuang  4 , Horng Yuan Wang  5 , Kuo Chih Tseng  6 , Ting Tsung Chang  7 , Jenny Yang  8 , Benedetta Massetto  8 , Vithika Suri  8 , Gregory Camus  8 , Deyuan Jiang  8 , Fangqiu Zhang  8 , Anuj Gaggar  8 , Tsung Hui Hu  9 , Yu Chun Hsu  10 , Gin Ho Lo  11 , Chi Jen Chu  12 , Jyh Jou Chen  13 , Cheng Yuan Peng  14 , Rong Nan Chien  15 , Pei Jer Chen  16
Affiliations

Ledipasvir/Sofosbuvir for Patients Coinfected With Chronic Hepatitis C and Hepatitis B in Taiwan: Follow-up at 108 Weeks Posttreatment

Chun Jen Liu et al. Clin Infect Dis. .

Abstract

Background: For patients coinfected with hepatitis C virus (HCV) and hepatitis B virus (HBV), HCV treatment with direct-acting antivirals can lead to HBV reactivation. We evaluated HBV reactivation during ledipasvir/sofosbuvir treatment and 108-week follow-up.

Methods: In Taiwan, 111 patients with HCV genotype 1 or 2 and HBV received ledipasvir/sofosbuvir (90mg/400mg) once daily for 12 weeks. HBV virologic reactivation was defined as postbaseline increase in HBV DNA from either less than the lower limit of quantification (LLOQ, 20 IU/mL) to equal to or more than LLOQ or equal to or more than LLOQ to >1 log10 IU/mL. HBV clinical reactivation was HBV virologic reactivation with alanine aminotransferase (ALT) >2× upper limit of normal. Factors associated with development of HBV virologic or clinical reactivation were evaluated with logistic regression analysis.

Results: All patients (100%, 111/111) maintained HCV suppression through 108 weeks after treatment. HBV virologic reactivation occurred in 73% of patients (81/111). Clinical reactivation occurred in 9% (10/111). The majority of HBV virologic reactivations (86%, 70/81) occurred by follow-up week 12, whereas clinical reactivation was generally more delayed. Eight (7%, 8/111) initiated HBV therapy. In regression analyses, baseline HBV DNA and hepatitis B surface antigen (HBsAg) levels were associated with HBV virologic reactivation and baseline ALT and HBV DNA, and HBsAg levels were associated with HBV clinical reactivation.

Conclusion: Among HCV/HBV coinfected patients treated with direct-acting antivirals for HCV, HBV virologic reactivation occurred in a majority of patients during treatment and follow-up. In most patients, HBV virologic reactivation was asymptomatic; only a small proportion initiated HBV treatment. Notably, clinical reactivation may still occur >3 months after end of therapy.

Clinical trials registration: NCT02613871.

Keywords: alanine aminotransferase; coinfection; hepatitis B surface antigen; reactivation.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. C.-J.L. has served as a consultant for Gilead Sciences, Inc., AbbVie, BMS, and Spring Bank; has given sponsored lectures for Gilead Sciences, Inc., AbbVie, BMS, and MSD; and has received grants from MSD. W.-L.C. has served as a consultant for Gilead Sciences, Inc., AbbVie, BMS, Roche, and PharmaEssentia, and has given sponsored lectures for Gilead Sciences, Inc., AbbVie, BMS, MSD, and Roche. T.-H.H. has served as a consultant for Gilead Sciences, Inc., AbbVie, BMS, and PharmaEssentia; has given sponsored lectures for Gilead Sciences, Inc., AbbVie, BMS, and MSD; and has received grants from Gilead Sciences, Inc. J.Y., B.M., V.S., G.C., D.J., F.Z., and A.G. are employees of Gilead Sciences, Inc., and may hold stock interest in the company. C.-J.C. has given sponsored lectures for Gilead Sciences, Inc., and BMS. P.-J.C. has received grants from Roche, BMS, and J&J; has served as a consultant for BMS, Roche, Bayer, MSD, and Taiha; and has given sponsored lectures for BMS and received honorarium for reviewing grant applications for LDA as a reviewer for Gilead Research Program grant, Liver Disease Asia.

Figures

Figure 1.
Figure 1.
Timing of hepatitis B virologic and clinical reactivation. EOT, end of treatment; FU, follow-up.
Figure 2.
Figure 2.
Kinetics of HBsAg during and 48 weeks after end of DAA. A, Mean change in HBV DNA and HBsAg from baseline. P value was determined using Spearman correlation. ∗Spearman correlation factor between HBsAg change and HBV DNA change during treatment. B, HBsAg change in patients with or without HBV reactivation. P value was determined using the Wilcoxon 2-sample test. DAA, direct-acting antiviral; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Liu CJ, Liou JM, Chen DS, Chen PJ.. Natural course and treatment of dual hepatitis B virus and hepatitis C virus infections. J Formos Med Assoc 2005; 104:783–91. - PubMed
    1. Liaw YF, Chen YC, Sheen IS, Chien RN, Yeh CT, Chu CM.. Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. Gastroenterology 2004; 126:1024–9. - PubMed
    1. Donato F, Boffetta P, Puoti M.. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998; 75:347–54. - PubMed
    1. Huang YT, Jen CL, Yang HI, et al. . Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C. J Clin Oncol 2011; 29:3643–50. - PMC - PubMed
    1. Stroffolini T, Sagnelli E, Sagnelli C, et al. . The burden of HBV infection in HCV patients in Italy and the risk of reactivation under DAA therapy. Dig Liver Dis 2019; 51:434–7. - PubMed

Publication types

Associated data